Dr. Amanda L. Jackson, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Medical University of South Carolina College of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 182
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: Medical University of South Carolina College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
OH license 35 123680 -
Obstetrics & Gynecology Physician
RI license LP01231
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Cincinnati Medical Center, LLC Cincinnati, OH
- Christ Hospital Cincinnati, OH
- West Chester Hospital West Chester, OH
Medical groups
- University of Cincinnati Physicians Company LLC (1,506 clinicians)
- Christ Hospital Medical Specialists LLC (125 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 182
- Services billed
- 726
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 145 | 42 |
| Established patient office or other outpatient visit, 30-39 minutes | 130 | 88 |
| New patient office or other outpatient visit, 60-74 minutes | 35 | 35 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 29 | 20 |
| Established patient office or other outpatient visit, 20-29 minutes | 21 | 20 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 16 | 16 |
| Exam of external female genitals using an endoscope | 13 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Lynparza (olaparib) | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 10 payments worth $1,621 in total to this clinician.
| Medical Device Business Services, Inc. | $1,389 |
|---|---|
| Genmab U.S., Inc. | $121 |
| AstraZeneca Pharmaceuticals LP | $111 |
| Travel and Lodging | $1,101 |
|---|---|
| Food and Beverage | $520 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Medical Device Business Services, Inc. Oct 10, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $779 |
| Medical Device Business Services, Inc. Oct 10, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $272 |
| Medical Device Business Services, Inc. Oct 10, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $50.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $14,903 in research payments for these studies, mostly to the institutions running them.
- Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie Inc. · Active, not recruiting · NCT05445778 - A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer.
Genmab U.S., Inc. - A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Karyopharm Therapeutics Inc. - Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
Genmab U.S., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.